clinical trial · NCT07459998
SKB103 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·phase2·not yet recruiting·n = 277
Advanced Solid TumorsSKB103 for injection monotherapy
brief summary
This is a phase 1/2 clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.
started
Apr 30, 2026
primary completion
Dec 31, 2029
completion
Dec 31, 2030
last updated
Mar 10, 2026
detailed description
This is a multi-center, open-label, phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics (PK) characteristics, immunogenicity, and efficacy of SKB103 in participants with advanced solid tumors. The study includes a Phase 1 dose escalation stage, a Phase 1 dose expansion stage, and a Phase 2 indication expansion stage.
official title
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SKB103 for Injection in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol